The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
Open accessAbstract
Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the Intensity of Conditioning Regimens: Working Definitions
Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., Apperley, J., Slavin, S., Pasquini, M., Sandmaier, B. M., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.07.004 · Cited by 1,816
Self-citationGiralt, S., Ballen, K. K., Rizzo, D., Bacigalupo, A., Horowitz, M. M., Pasquini, M. C., & Sandmaier, B. M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.12.497 · Cited by 902
Self-citationMuffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., Aljurf, M., Ballen, K. K., Bajel, A., Baron, F., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772368 · Cited by 297
Self-citationKanate, A. S., Majhail, N. S., Savani, B. N., Bredeson, C., Champlin, R. E., Crawford, S., Giralt, S. A., LeMaistre, C. F., Marks, D. I., Omel, J. L., et al. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2020.03.002 · Cited by 283
Self-citationJain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.015 · Cited by 191
Self-citationSchriber, J. R., Hari, P., Ahn, K. W., Fei, M., Costa, L. J., Kharfan-Dabaja, M. A., Díaz, M. Á., Gale, R. P., Ganguly, S., Girnius, S. K., et al. (2017) · Cancer · doi:10.1002/cncr.30747 · Cited by 88
Self-citationFDA approves axicabtagene ciloleucel for large B-cell lymphoma
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm581296.htm · Cited by 25
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Kumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N., Singh, A. K., Parker, T. L., Menter, A., Yang, X., Parsons, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30452-6 · Cited by 245
Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations
Baumrin, E., Loren, A. W., Falk, S. J., Mays, J. W., & Cowen, E. W. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.12.024 · Cited by 59
Retracted
Metadata
- Authors
- D'Souza, A., Fretham, C., Lee, S. J., Arora, M., Brunner, J., Chhabra, S., Devine, S., Eapen, M., Hamadani, M., Hari, P., Pasquini, M. C., Perez, W., Phelan, R. A., Riches, M. L., Rizzo, J. D., Saber, W., Shaw, B. E., Spellman, S. R., Steinert, P., Weisdorf, D. J., & Horowitz, M. M.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 26
- Issue
- 8
- Pages
- e177-e182
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2621741324
- Cited by
- 712
- References
- 7
- FWCI
- 58.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.